What is the difference between MMSC (methylmalonic‑acidemia, cobalamin‑C type) and the FAB (French‑American‑British) classification system?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

MMSC vs FAB: Distinct and Unrelated Medical Entities

MMSC (methylmalonic acidemia, cobalamin C type) and FAB (French-American-British classification) are completely different medical concepts that should not be compared—MMSC refers to a specific inherited metabolic disorder, while FAB is a morphology-based classification system for hematologic malignancies.

Understanding Each Entity

FAB Classification System

The French-American-British (FAB) classification is a morphology-based system dating from 1976 that categorizes acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) based on blast cell appearance under light microscopy using cytochemical stains 1.

Key FAB characteristics:

  • Requires ≥30% blast cells in bone marrow or peripheral blood for AML diagnosis 2, 1
  • Uses Wright or Wright-Giemsa staining with assessment of malignant cell lines 1
  • Applicable only to untreated patients (chemotherapy alters morphology) 1
  • Classifies MDS into subtypes: RA, RARS, RAEB, RAEB-T, and CMML 3

Critical limitation: FAB has been largely superseded by the WHO classification system, which is now the gold standard 1, 4. The WHO classification (first edition 2001, revised 2016) incorporates genetic features, immunophenotype data, and clinical information—not just morphology 1. The WHO lowered the blast threshold to 20% and recognizes that certain cytogenetic abnormalities [t(8;21), t(15;17), inv(16)] establish AML diagnosis regardless of blast percentage 2, 1, 5.

MMSC (Cobalamin C Deficiency)

MMSC, more accurately termed cblC deficiency or cobalamin C disease, is an autosomal recessive inherited metabolic disorder caused by biallelic pathogenic variants in the MMACHC gene 6, 7, 8. This is the most common inborn error of cobalamin (vitamin B12) metabolism 9, 7.

Clinical manifestations include:

  • Multisystem involvement: neurological dysfunction (microcephaly, seizures, developmental delay, ataxia), hematologic abnormalities, renal disease (thrombotic microangiopathy), cardiovascular complications 9, 8
  • Biochemical hallmarks: elevated methylmalonic acid and homocysteine 6, 10
  • Can present from neonatal period to adulthood 6, 10
  • Life-threatening complications: aortic dissection, pulmonary arterial hypertension, acute kidney injury 6, 8

Treatment approach:

  • High-dose hydroxocobalamin (vitamin B12) is the mainstay therapy 7, 11
  • Adjunctive therapy: betaine, levocarnitine, folic acid 7, 8
  • Long-term hydroxocobalamin is well-tolerated even at higher doses with prolonged treatment 11
  • Early diagnosis and treatment initiation are critical for outcomes 9, 7

Why This Comparison is Inappropriate

These are fundamentally different medical concepts:

  • FAB = A classification methodology for categorizing blood cancers
  • MMSC/cblC = A specific genetic metabolic disease entity

The only potential source of confusion might be that both involve hematologic abnormalities, but they operate in completely different diagnostic and therapeutic frameworks. A patient with cblC deficiency may have anemia or other blood abnormalities 9, but these would not be classified using FAB criteria, which specifically applies to myeloid malignancies.

If you are encountering these terms together in a clinical context, clarify whether:

  • You're asking about MDS (myelodysplastic syndrome) vs FAB classification
  • You're asking about a patient with cblC deficiency who has concurrent hematologic findings
  • There's been a terminology mix-up in documentation

References

Guideline

acute myelogenous leukemia - current recommendations and approaches in molecular-genetic assessment.

Romanian journal of internal medicine = Revue roumaine de medecine interne, 2022

Guideline

acute myeloid leukemia.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

Guideline

myelodysplastic syndromes: clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.